Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report ‘seeding’ this accumulation through fragments of the culprit ...

A therapy using a patient's own proximal basal stem cells shows promise to treat idiopathic pulmonary fibrosis.

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

A machine learning algorithm developed by Cambridge scientists was able to correctly identify in 97 cases out of 100 whether ...

Our immune systems develop to recognize what is foreign within our bodies. As immune cells are generated in the bone marrow ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

TFE3 fusion proteins are the oncogenic drivers of translocation renal cell carcinoma but their mechanism of action remains ...

Candel Therapeutics (CADL) announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, ...

Scientists have developed a new method that can grow motor neurons from skin cells, which may serve as a platform for ALS ...

"The findings uncover a new way in which the immune system is suppressed, limiting T cells from fighting cancer spread. This ...

To determine the underlying causes of neuronal vulnerability at the earliest stages of Alzheimer's Disease (AD), a research ...